Cartesian Therapeutics Secures $130 Million in PIPE Financing Amid Announcement of First Patient Dosed in Phase 2 Trial for mRNA Cell Therapy Cartesian Therapeutics, Inc. has secured $130 million in [….]
Selecta Biosciences and Cartesian Therapeutics Announce Merger to Form Public Company Focused on RNA Cell Therapy
Join RNA leaders, experts and distinguished scientists in Europe, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations within the formulation [….]
An intensive 2-day in person meeting that delves into the latest in vaccine research, platform technologies, development and manufacturing & a meeting place for experts working within cutting-edge vaccine research [….]
George Mason University bioengineering professor Michael Buschmann and a team of scientific collaborators have devised improved lipid nanoparticle technologies to deliver mRNA that could make mRNA vaccines such as the COVID-19 vaccines less costly, with fewer side-effects and more available worldwide.
Danaher Corporation (NYSE: DHR) (the “Company”) announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper.
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without [….]
With the unprecedented speed of vaccine development amid the COVID-19 pandemic, questions have emerged regarding the future of vaccinology beyond the coronavirus. In a panel on vaccinology in the 21st century hosted by Noble Life Sciences, scientists discussed the vaccine platforms available to us now, the significance of mRNA vaccines and the emergence of new combination vaccines.
